The biotech sector is experiencing a robust resurgence, marked by significant investment, strategic mergers and acquisitions, and groundbreaking clinical advancements,…
Read More
Beyond PD-1: The drugs reshaping cancer treatment at ASCO 2026
The global biotechnology sector is experiencing a significant resurgence, marked by robust investment, strategic mergers and acquisitions, and groundbreaking scientific…
Read More
Radiopharmaceuticals Ascend: ASCO 2026 Highlights Evolving Cancer Treatment Landscape
The burgeoning field of radiopharmaceuticals, propelled by the success of treatments like Novartis’s Pluvicto (lutetium Lu 177 vipivotide tetraxetan), is…
Read More
Beyond PD-1: The Drugs Reshaping Cancer Treatment at ASCO 2026
The biomedical sector is once again experiencing a vibrant resurgence, marked by robust investment, strategic mergers and acquisitions (M&A), and…
Read MoreBeyond PD-1: The drugs reshaping cancer treatment at ASCO 2026
The biotechnology sector, a critical engine of medical innovation, is experiencing a robust resurgence, marking a significant turnaround from recent…
Read More
ASCO 2026: Navigating the Evolving Landscape of Non-Small Cell Lung Cancer with Promising Data from Eli Lilly and Mixed Reactions for Summit/Akeso
The American Society of Clinical Oncology (ASCO) 2026, held from May 29 to June 2, 2026, served as a critical…
Read More
ASCO 2026 Delivers Promising Advances and Crucial Data in Blood Cancer Treatment
The 2026 American Society of Clinical Oncology (ASCO) conference, a cornerstone event for oncological advancements, has concluded, leaving a significant…
Read More
Lilly’s $7bn Acquisition of Kelonia Bears Fruit as In Vivo Cell Therapies Show Significant Promise at ASCO 2026
The American Society for Clinical Oncology (ASCO) meeting in 2026, a cornerstone event for oncological advancements, has concluded, leaving behind…
Read More
ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma – Pharmaceutical Technology
The rapidly evolving landscape of multiple myeloma treatment is witnessing a pivotal moment with the emergence of in vivo chimeric…
Read More
ASCO 2026: Lung Cancer Landscape Ignites with Promising Bispecifics, Targeted Therapies, and Extended Survival Data
The annual American Society of Clinical Oncology (ASCO) congress, a cornerstone event for the global oncology community, convened in Chicago,…
Read More
